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A B S T R A C T
Background
Treating vaso-occlusive painful crises in people with sickle cell disease is complex and requires multiple interventions. Extra fluids are
routinely given as adjunct treatment, regardless of the individual’s state of hydration with the aim of slowing or stopping the sickling
process and thereby alleviating pain. This is an update of a previously published Cochrane Review.
Objectives
To determine the optimal route, quantity and type of fluid replacement for people with sickle cell disease with acute painful crises.
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises of references identified from
comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.
We also conducted searches of Embase (November 2007), LILACS, www.ClinicalTrials.gov (05 January 2010), and theWHO ICTRP
(30 June 2017).
Date of most recent search of the Group’s Haemoglobinopathies Trials Register: 16 February 2017.
Selection criteria
Randomised and quasi-randomised controlled trials that compared the administration of supplemental fluids adjunctive to analgesics
by any route in people with any type of sickle cell disease during an acute painful episode, under medical supervision (inpatient, day
care or community).
Data collection and analysis
No relevant trials have yet been identified.
Main results
Sixteen trials were identified by the searches, all of which were not eligible for inclusion in the review.
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Authors’ conclusions
Treating vaso-occlusive crises is complex and requires multiple interventions. Extra fluids, generally oral or intravenous, are routinely
administered during acute painful episodes to people with sickle cell disease regardless of the individual’s state of hydration. Reports of
their use during these acute painful episodes do not state the efficacy of any single route, type or quantity of fluid compared to another.
However, there are no randomised controlled trials that have assessed the safety and efficacy of different routes, types or quantities of
fluid. This systematic review identifies the need for a multicentre randomised controlled trial assessing the efficacy and possible adverse
effects of different routes, types and quantities of fluid administered to people with sickle cell disease during acute painful episodes.
P L A I N L A N G U A G E S U M M A R Y
Replacing fluids to treat acute episodes of pain in people with sickle cell disease
Review question
To assess the best route, quantity and type of fluid replacement for people with sickle cell disease with acute painful crises.
Background
Sickle cell disease is a common genetic disorder characterised by periodic episodes of pain which usually happen again and again
throughout life. These episodes occur when sickled cells obstruct blood vessels. The degree of pain may range from a mild discomfort
to a severe disabling pain where the person needs treatment in hospital. A drop in body fluid levels promotes and sustains the sickling
process. Routine treatment includes the use of drugs to relieve pain and the maintenance of adequate fluid levels. Fluid levels will fall if
insufficient fluids are taken in compared to the amount of fluid lost. The kidneys of people with sickle cell disease do not concentrate
urine properly, which results in poor control of bodily fluids. Additional fluids are given to try and slow or stop the sickling process
which should reduce the amount and duration of pain. Fluids may be given in many ways, but orally or intravenously are most common.
Fluids should be given with care so as to prevent fluid overload which may in turn cause adverse events such as heart failure or fluid
building up in the lungs. We looked for randomised controlled trials to show the best way to replace fluids, which type of fluids and
how much fluid to replace to treat acute episodes of pain in people with sickle cell disease. This is an update of a previously published
Cochrane Review.
Search date
The evidence is current to: 16 February 2017.
Trial characteristics
We did not find any randomized controlled trials (trials where the people taking part are put into different treatment groups completely
at random) which we could include in the review.
Key results
We conclude that there is a need for large multi-centre trials to assess fluid replacement therapy for people with sickle cell disease with
acute painful crises.
B A C K G R O U N D
Description of the condition
Sickle cell disease (SCD) is comprised of a group of autosomal re-
cessive haemoglobin disorders characterised by the production of
abnormal haemoglobin, haemoglobin S (HbS). The common fea-
ture in SCD is the presence of the sickle gene either homozygous or
heterozygous. Sickle cell anaemia (HbSS) occurs as a result of ho-
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mozygous inheritance of the sickle gene and is the most common
and severe form of the disease (Serjeant 1992).Other clinically sig-
nificant diseases are compound heterozygous conditions, in which
the sickle haemoglobin interacts with other haemoglobins, such as
haemoglobin C (HbSC) or β-thalassaemia (HbSb+ and HbSb0)
(Lane 2001a).
Acute painful or vaso-occlusive crisis is the most common man-
ifestation of SCD (Steinberg 2006). These painful episodes are
periodic, often recurrent, and may occur throughout life; among
women of child-bearing age, vaso-occlusive crisis tends to occur
more frequently during pregnancy (Adam 1996). The range of
duration of painful crises remains unclear; pain often lasts for be-
tween four and six days butmay persist for weeks (Steinberg 1999).
The pain rate (number of episodes per year) has been used as a
proxy to identify people with poor clinical outcome as it correlates
well with early death in people with sickle cell anaemia between
the second and third decade of life (Platt 1991). However, in peo-
ple less than 20 years of age, no correlation exists between pain
and mortality. People who experience three or more acute painful
episodes per year requiring treatment with parenteral opioid anal-
gesics in a medical facility for four or more hours are considered
to have a poor clinical outcome (Charache 1995).
Description of the intervention
The treatment of acute painful crises is at present predominantly
symptomatic, comprising of: pharmacological agents (non-opioid
and opioid analgesics with or without adjuvants); non-pharmaco-
logic approaches (heat or ice packs, relaxation, acupuncture, self-
hypnosis); as well as other measures such as packed red cell trans-
fusion, oxygen therapy, the treatment of associated infections and
fluid replacement therapy (Ballas 2005; Ballas 2007; De Ceulaer
1982; Gaston 1986; Lane 2001a). Fluid replacement therapy is of
paramount importance because dehydration from insensible water
loss, reduced fluid intake and polyuria causes a reduction in plasma
volume with an increase in blood viscosity, which promotes and
sustains the sickling process (Adekile 1999). Hyposthenuria, the
inability to concentrate urine, is the most common renal abnor-
mality in people with SCD (Allon 1990; Kontessis 1992). This
functional impairment in the concentrating mechanism arises due
to hypoxia in the renal tubules and as a consequence of subclin-
ical intravascular sickling in the hypertonic renal medulla (Keitel
1956). Hyposthenuria is most marked in HbSS (Statius van Eps
1967). As a result of hyposthenuria, people with SCD produce a
higher than usual obligatory urine output and are more susceptible
than normal individuals to dehydration (Saborio 1999). During
episodes of illness, people with SCD often decrease their intake
of fluids and may become dehydrated. While people with SCD
in painful crisis may not be clinically dehydrated, their red blood
cells are known to be dehydrated (Brugnara 1995).
How the intervention might work
Sickling of red blood cells is dependent on the intracellular con-
centration of deoxyhaemoglobin S which in turn is a function
of the osmolality of the plasma. The aim of hydrating people in
painful crisis is to slow or stop the sickling process by increasing the
plasma volume, thereby decreasing blood viscosity and indirectly
reducing red cellular dehydration as well as the intracellular con-
centration of Haemoglobin S. It has been suggested that routinely
giving extra oral fluids in mild vaso-occlusive crisis shortens the
episode and relieves pain (Steinberg 1999). Supplemental fluids
may be given either orally or intravenously, nasogastrically, subcu-
taneously or rectally. By inducing severe dilutional hyponatremia
(abnormally low levels of blood sodium) in people with SCDusing
a vasopressin analogue and 5% dextrose in water (5DW) or half
normal saline as fluid therapy as well as dietary salt restriction, it is
possible to reduce the mean red cell haemoglobin S concentration
(Rosa 1980). This, however, may be associated with severe adverse
effects and is not a consistent finding (Charache 1981; Charache
1983). The use of 5DW or half normal saline as fluid therapy in-
stead of normal saline has not been demonstrated to significantly
affect the intracellular concentration of Haemoglobin S, or to pre-
vent or abort painful crises (Charache 1983). In children and ado-
lescents between one and one-and-a-half times the estimated daily
fluid maintenance requirements are recommended (Lane 2001b).
Increased fluids may be needed if the individual is dehydrated or
insensible losses are increased as in persistent fever, or both. The
recommendations for adults is that fluid replacement is adminis-
tered at an hourly rate of 250mL for eight hours, and then reduced
to 125 mL hourly if there are no signs or past history of conges-
tive heart failure or renal failure (SCIC 2005). For those receiving
opioids for pain, fluids should be given with care; opiates decrease
cardiac output and fluid overload could precipitate heart failure.
In people with acute chest syndrome, fluids are usually given at
daily maintenance levels, as over-hydration could cause regions of
pneumonitis to develop (SCIC 2005). The clinical effectiveness of
fluid replacement therapy for treating painful sickle crisis during
pregnancy is, however, not known (Martí-Carvajal 2009).
Why it is important to do this review
Treating a vaso-occlusive crisis is complex and requires multiple
interventions. The routine administration of extra fluids, regard-
less of the individual’s state of hydration, is currently advocated
as a potentially beneficial adjunctive treatment in this condition.
However, a systematic review of available evidence on the bene-
fits and actual reported harms of fluid supplementation and the
routes of supplementation is needed to clarify the uncertainties
surrounding this intervention.
This is an update of previously published versions of this review
(Okomo 2007; Okomo 2012; Okomo 2015).
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O B J E C T I V E S
To determine the optimal route and quantity of fluid replacement
for people with SCDwith acute painful crises. A post hoc objective
is to determine, where possible, the most appropriate type of fluid
replacement for any route of administration.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised or quasi-randomised controlled trials. We had
planned to include trials in which quasi-randomised methods,
such as alternation were used, if there was sufficient evidence that
the treatment and control groups were similar at baseline.
Types of participants
People with SCD (SS, SC, Sb+ and Sb0) proven by electrophoresis
and sickle solubility test, with family studies or DNA tests as ap-
propriate, of all ages and both sexes in any setting (both developed
and developing countries).
Types of interventions
We reviewed all studies that compared the administration of sup-
plemental fluids adjunctive to analgesics by any route in people
with any type of sickle cell disease during an acute painful episode,
under medical supervision (inpatient, day care or community).
We had planned to also consider secondary comparisons between
different fluid types and quantity of fluid administered if a suitable
number of adequately sized trials had been identified, including
between the different types of sickle cell disease.
Types of outcome measures
Primary outcomes
1. Duration of pain crisis
Secondary outcomes
1. Length of hospital stay (for hospitalised patients)
2. Pain severity
i) score
ii) analgesia use
3. Reported adverse events such as:
i) fluid overload (pedal oedema, pulmonary oedema)
ii) iatrogenic infections (thrombophlebitis)
iii) other
4. Development of major sickle complication, e.g. acute chest
syndrome (ACS), acute splenic sequestration (ASS),
cerebrovascular accident (CVA)
5. Death
Search methods for identification of studies
Electronic searches
Relevant trials were searched for in
the Group’s Haemoglobinopathies Trials Register using the terms:
(sickle cell OR (haemoglobinopathies AND general)) AND pain
AND hydration. There were no restrictions regarding language or
publication status.
The Haemoglobinopathies Trials Register is compiled from elec-
tronic searches of theCochraneCentral Register of ControlledTri-
als (CENTRAL) (updated each new issue of theCochrane Library)
and weekly searches of MEDLINE. Unpublished work is iden-
tified by searching the abstract books of five major conferences:
the EuropeanHaematology Association conference; the American
Society of Hematology conference; the British Society for Haema-
tology Annual Scientific Meeting; the Caribbean Public Health
AgencyAnnual ScientificMeeting (formerly theCaribbeanHealth
Research Council Meeting); and the National Sickle Cell Disease
Program Annual Meeting. For full details of all searching activities
for the register, please see the relevant section of the Cochrane
Cystic Fibrosis and Genetic Disorders Group’s website.
We also conducted searches of Embase, LILACS, the WHO IC-
TRP and the website www.ClinicalTrials.gov. Please refer to the
’Appendices’ section of the review for further details (Appendix 1;
Appendix 2; Appendix 3).
Date of the last search of the Group’s Haemoglobinopathies Trials
Register: 16 February 2017.
Data collection and analysis
Selection of studies
The two authors independently screened the 16 trials found by
the searches of all the databases and reference lists to identify pa-
pers with potential relevance to the review. Only one potentially
relevant article was found, the full text of which was obtained and
translated into English. We were not blinded to trial authors, in-
stitutions, journal of publication or trial results.
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Data extraction and management
When trials are included in the review, data extraction will be
undertaken by each author. Data will be extracted with a data
extraction form developed by the authors. Disagreements will be
resolved by consensus between the authors.
We planned to compare outcomes measured at 1, 4, 8, 12 and
24 hours after commencement of treatment, and daily thereafter
(where in-patient facilities exist, until discharge from hospital).
Assessment of risk of bias in included studies
When trials are included in the review, each author will assess
every trial using a simple form and will follow the domain-based
evaluation as described in theCochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
We aimed to assess the following domains as either a low, unclear,
or high risk of bias:
1. randomisation;
2. concealment of allocation;
3. blinding (of participants, personnel and outcome assessors);
4. incomplete outcome data;
5. selective outcome reporting.
Measures of treatment effect
As no trials have yet been included in the review, we are unable to
carry out any analysis. However, we had intended to analyse binary
data using an odds ratio (OR)with 95%confidence intervals (95%
CI). We planned to analyse continuous data using weighted mean
differences (WMDs) if outcomes weremeasured in a standard way
across trials, or standardised mean differences (SMDs) if outcomes
were conceptually the same but measured in different ways, along
with 95% CIs.
Dealing with missing data
Missing data will be requested from the original investigators.
Assessment of heterogeneity
We planned to quantify the impact of statistical and clinical het-
erogeneity in the meta-analysis using a measure of the degree of
inconsistency in the trials’ results (Higgins 2003). This measure
(I²) describes the percentage of total variation across studies that
are due to heterogeneity rather than chance (Higgins 2003). The
values of I² lie between 0% and 100%, and a simplified categori-
sation of heterogeneity that we planned to use is of low (I² value
of 25%), moderate (I² value of 50%), and high (I² value of 75%)
(Higgins 2003).
Assessment of reporting biases
We were to examine publication bias using a funnel plot, assessed
visually and quantitatively, and use meta-regression to look for
associations between key measures of trial quality and treatment
size.
Data synthesis
Where heterogeneity was found to be statistically significant, we
intended to use the random-effects model of statistical analysis.
Where it was found not to be statistically significant, we would
have used a fixed-effect model.
Subgroup analysis and investigation of heterogeneity
If we had found heterogeneity, we planned to investigate the pos-
sible causes further.We had intended to examine for methodolog-
ical and statistical heterogeneity if they were encountered. Fur-
thermore, had there been sufficient numbers of adequately-sized
trials, we would have assessed clinical heterogeneity by subgroup
analysis, stratified according to sickle status: ’severe genotypes’ (SS
and Sb0) and ’mild genotypes’ (SC and Sb+); severity of disease
(number of episodes per year); age (child and adult) and setting
(developed versus developing countries).
Sensitivity analysis
We planned to perform a sensitivity analysis based on themethod-
ological quality of the trials, including and excluding quasi-ran-
domised trials.
R E S U L T S
Description of studies
No trials have been identified which are eligible for inclusion in
the review.
The trials listed as ’Excluded studies’ were not eligible for in-
clusion for all or some of the following reasons: the randomisa-
tion was unclear; the studies were not RCTs or quasi-RCTs; the
trial participants or interventions (or both) were not relevant to
the review; the authors could not be contacted for further clari-
fication (Alvim 2005; Beiter Jr 2001, Charache 1981, Charache
1983, de Araujo 1994, Gonzalez 1988; Gonzalez 1991, Guy
1971, Guy 1973, Hardwick Jr 1999, Hatch 1965, Kalinyak 2005,
Nalbandian 1971, Orringer 2001, Oski 1965, Rhodes 1974).
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Risk of bias in included studies
No trials eligible for inclusion in this review have been identified.
Effects of interventions
No trials eligible for inclusion in this review have been identified.
D I S C U S S I O N
It is surprising that despite the widespread prevalence of sickle cell
disease and the well described nature of the acute painful episodes
that are its most common manifestation, there are no randomised
controlled trials to provide evidence for the routine use of extra
fluids of any type and by any route during acute episodes of pain in
people with sickle cell disease. The result of one non-randomised
study had suggested that oral hydration alone is inadequate to
maintain the hydration status and that vigorous intravenous fluid
therapy provides the quickest and most effective method of restor-
ing a satisfactory state of hydration during acute episodes of pain
(Hatch 1965). The report of another non-randomised controlled
trial suggested that treatment of sickle cell crisis with rapid in-
fusion of hypotonic saline can lower serum osmolality, decreases
pain and is well tolerated (Guy 1971). Intravenous urea in sugar
solutions have also been shown to abort sickle cell crises in the
absence of narcotics and analgesics (Nalbandian 1971). However,
this also required the co-administration of Ringer’s lactate to pre-
vent dehydration consequent upon the profound diuresis caused
by the urea solution. Themethodological limitations of these stud-
ies made it inappropriate to draw valid conclusions from them.
The authors embarked upon a randomised controlled study but
no information on this was found in any of the database searches.
In the absence of randomised controlled trials that assessed the
effects of different types of supplemental fluids given through any
route in sickle cell painful crisis, this systematic review found no
evidence to either support or refute these observations.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
No conclusions can be drawn at the present time about the effec-
tiveness of fluid replacement therapy of any type for acute painful
crises in people with sickle cell disease nor about the optimal mode
of delivery.
Implications for research
The absence of randomised controlled trials of fluid replacement
therapy in sickle cell disease as shown by this extensive literature
search is not justified. Research is needed in this area, and this
should take into account both demographic and clinical variables.
Well-designed, adequately-powered trials should incorporate peo-
ple of different age groups, social background and ethnic classifi-
cations. The trial design should also take into account the types
of fluids, routes of administration and appropriate volumes. Mul-
ticentre collaboration may be needed. Outcomes to be assessed in
these trials should be such as would address the needs and con-
cerns of patients, care-givers and health providers. Similar out-
come measures should also be used in different patient groups and
across trial sites to facilitate comparability of results and future
synthesis of data in meta-analysis.
An appropriate review will be possible, if data are reported in the
publications describing trials in the future.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alvim 2005 1. Randomisation unclear
2. Interventions not relevant
3. Outcomes not relevant
Beiter Jr 2001 1. Study not RCT or quasi-RCT
2. Interventions not relevant
Charache 1981 1. Study not RCT or quasi-RCT
2. Interventions not relevant
Charache 1983 1. Study not RCT or quasi-RCT
2. Interventions not relevant
de Araujo 1994 1. Group allocation not clear (contacted authors several times for clarification, but to date have received no
reply)
Gonzalez 1988 1. Interventions not relevant
Gonzalez 1991 1. Study not RCT or quasi-RCT
2. Interventions not relevant
Guy 1971 1. Study not RCT or quasi-RCT
2. Interventions not relevant
Guy 1973 1. Study not RCT or quasi-RCT
Hardwick Jr 1999 1. Interventions not relevant
Hatch 1965 1. Study not RCT or quasi-RCT
2. Interventions not relevant
Kalinyak 2005 1. Participants not relevant
2. Interventions not relevant
Nalbandian 1971 1. Study not RCT or quasi-RCT
2. Interventions not relevant
Orringer 2001 1. Interventions not relevant
Oski 1965 1. Study not RCT or quasi-RCT
2. Interventions not relevant
Rhodes 1974 1. Interventions not relevant
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RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. EMBASE Search Strategy (November 2007)
Search terms
1. RANDOM$
2. FACTORIAL$
3. CROSSOVER$ OR CROSS ADJ OVER$
4. PLACEBO$
5. DOUBL$ ADJ BLIND$
6. SINGL$ ADJ BLIND$
7. ASSIGN$
8. ALLOCAT$
9. VOLUNTEER$
10. (CROSSOVER ADJ PROCEDURE).DE.
11. (DOUBLE ADJ BLIND ADJ PROCEDURE).DE.
12. (RANDOMIZED ADJ CONTROLLED ADJ TRIAL).DE.
13. (SINGLE ADJ BLIND ADJ PROCEDURE).DE.
14. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13
15. SICKLE ADJ CELL
16. SICKLE-CELL-ANEMIA#.DE. OR SICKLE-CELL#.DE.
17. 15 OR 16
18. HYDRATION
19. HYDRATION#.W..DE.
20. FLUID
21. FLUID ADJ REPLACEMENT
22. FLUID-THERAPY#.DE. 23. 18 OR 19 OR 20 OR 21 OR 22
24. 14 AND 17 AND 23
Appendix 2. LILACS Search Strategy (05 January 2010)
Search terms
1. ((Pt RANDOMIZED CONTROLLED TRIAL OR Pt CONTROLLED CLINICAL TRIAL ORMh RANDOMIZED CON-
TROLLED TRIALS OR Mh RANDOM ALLOCATION OR Mh DOUBLE-BLIND METHOD OR Mh SINGLE-BLIND
METHOD) ANDNOT (Ct ANIMALS ANDNOT (Ct HUMAN ANDCt ANIMALS)) OR (Pt CLINICAL TRIAL OR Ex E05.
318.760.535$) OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ OR Tw experim$ OR Tw investiga$)) OR ((Tw singl$
OR Tw simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND (Tw blind$ OR Tw cego$ OR
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(Continued)
Tw ciego$ OR Tw mask$ OR Tw mascar$)) OR Mh PLACEBOS OR Tw placebo$ OR (Tw random$ OR Tw randon$ OR Tw
casual$ OR Tw acaso$ OR Tw azar OR Tw aleator$) OR (Mh RESEARCH DESIGN) ANDNOT (Ct ANIMALS ANDNOT (Ct
HUMAN AND Ct ANIMALS)) OR (Ct COMPARATIVE STUDY OR Ex E05.337$ OR Mh FOLLOW-UP STUDIES OR Mh
PROSPECTIVE STUDIES OR Tw control$ OR Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) AND NOT (Ct ANIMALS
AND NOT (Ct HUMAN AND Ct ANIMALS))) AND NOTMh ANIMALS
2. AND ( sickle ) or “SICKLE” or “SICKLECELL”
3. AND ( ( fluid ) or “FLUID THERAPY” ) or ( ( hydration ) or ( liquido) or “HYDRATION”)
Appendix 3. Clinicaltrials.gov Search Strategy (05 January 2010)
Search terms
Sickle cell AND hydration
And also
Sickle cell AND fluid
Appendix 4. WHO International Clinial Trials Registry Platform search strategy (30 June 2017)
Search terms
Sickle cell
And acute pain
AND fluid
WH A T ’ S N E W
Last assessed as up-to-date: 3 July 2017.
Date Event Description
3 July 2017 New search has been performed A search of the Cochrane Cystic Fibrosis and Genetic
Disorders Haemoglobinopathies Trials Register and the
WHO ICTRP did not identify any potentially eligible tri-
als
3 July 2017 New citation required but conclusions have not changed Minor changes have been made throughout the review,
including the re-formatting of the plain language summary
in line with more recent guidelines
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H I S T O R Y
Protocol first published: Issue 3, 2005
Review first published: Issue 2, 2007
Date Event Description
4 March 2015 New search has been performed A search of the Cochrane Cystic Fibrosis and Genetic
Disorders Group’s haemoglobinopathies Trials Register
did not identify any potentially relevant trials for inclu-
sion in the review
4 March 2015 New citation required but conclusions have not
changed
The study by de Araujo has been moved to excluded
studies following unsuccessful attempts to contact the
authors for further clarification (de Araujo 1994).
27 April 2012 New citation required but conclusions have not
changed
Minor changes to the text have been made throughout
the review
9 February 2012 New search has been performed A search of the Group’s Haemoglobinopathies Trials
Register did not identify any trials eligible for inclusion
in this review
5 January 2010 New search has been performed A search of the Group’s Haemoglobinopathies Trials
Register did not identify any trials eligible for inclusion
in this review
Searches of LILACs andwww.ClinicalTrials.gov did not
identify any trials eligible for inclusion in the review
The Background section has been updated.
18 April 2008 New search has been performed A search of the Group’s Haemoglobinopathies Trials
Register did not identify any trials eligible for inclusion
in this review.
Comments by the CFGD Group’s Medical Statistician
have been addressed
18 April 2008 Amended Converted to new review format.
The original ’Synopsis’ has been replaced with a new
’Plain language summary’ in line with guidance from
The Cochrane Collaboration
21 February 2007 New citation required and conclusions have changed Review first published
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